{"prompt": "['PREDM', 'Page 31', 'with higher doses of metformin (maximum dose of metformin ER is 2000 mg) or', 'decreased renal function, however, the specific dosage level these effects may begin', 'to be observed has not been determined or was not available. These risks are', 'theoretical, however, in patients with renal dysfunction, consultation with a', 'pharmacist regarding risk and need for reduced dosing of metformin will occur for', 'any potentially eligible participants taking one of the following medications:', 'Cimetidine, Ranitidine, Proton Pump Inhibitors (PPIs), Trimethoprim, Cephalexin,', 'Dolutegravir, Pyrimethamine, Ranolazine, Vandetanib, Imatinib, Nilotinib,', 'Gefitinib, Erlotinib, Atenolol, or other cationic drugs including but not limited to', '(amiloride, digoxin, morphine, procainamide, quinidine, quinine, triamterene,', 'vancomyocin). 50,51', 'Carbonic Anhydrase Inhibitors:', 'Caution should be used with concurrent use of topiramate, zonisamide,', 'acetazolamide or dichlorphenamide as these medications often cause a decrease in', 'serum bicarbonate and subsequent non-anion gap, hyperchloremic metabolic', 'acidosis. Therefore, concomitant use may increase the risk for lactic acidosis.', 'Consider increased monitoring if participant is using these agents and has low', 'serum bicarbonate at baseline. 52,53', 'Insulin Secretagogues or Insulin:', 'Co-administration of metformin with other agents used for diabetes control that', 'lower blood glucose levels increases the risk for clinically significant', 'hypoglycemia. Participants with diabetes at baseline are ineligible to participate and', 'those who develop diabetes will be removed from the study. As a result, no', 'participants should be co-administered other hypoglycemic agents used in diabetes', 'management while enrolled on this protocol. Appendix contains disallowed drugs', 'list and drugs that will be tracked on study.', '5.5 Supportive Care', 'All participants will be advised regarding the risk of metformin use in the setting of', 'new onset renal dysfunction, heart failure, liver failure, excessive alcohol use and at', 'the time of studies utilizing iodinated contrast. Participants will be advised to', 'contact the study team if they are hospitalized for any reason or if they are notified', 'of new changes to their health status. However, these relative contraindications to', 'metformin use are well known in the medical community and all participants should', 'receive care as per best medical practice. As metformin is a commonly used', 'medication for the treatment of diabetes and its prevention, and participants are not', 'blinded to their receipt of metformin, they should notify any medical provider', 'responsible for their care of their metformin use at the time of any routine or', 'emergent healthcare encounter.', '6.0 DRUG INFORMATION', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 32', 'METFORMIN (Brand NameTM D-Care DM2 [DSC]; Fortamet; Glucophage;', 'Glucophage XR; Glumetza; Riomet; Riomet ER)', 'Source and Pharmacology: Metformin hydrochloride tablets, USP contain the', 'antihyperglycemic agent Metformin, which is a biguanide, in the form of', 'monohydrochloride. The chemical name of Metformin hydrochloride', 'is N,Ndimethylimidodicarbonimidic diamide hydrochloride. Metformin', 'hydrochloride, USP is a white to off-white crystalline compound with a molecular', 'formula of C H N HCl and a molecular weight of 165.63. Metformin', 'hydrochloride is freely soluble in water, slightly 4 11 5 soluble in alcohol,', 'practically insoluble in acetone and in methylene chloride. The pKa of Metformin is', '12.4. The pH of a 1% aqueous solution of Metformin hydrochloride is 6.68.', 'Metformin hydrochloride tablets, USP contain 500 mg, 850 mg, or 1000 mg of', 'Metformin hydrochloride, which is equivalent to 389.93 mg, 662.88 mg, 779.86 mg', 'Metformin base, respectively. Each tablet contains the inactive ingredients', 'povidone (K-30), povidone (K-90), pregelatinized starch, and magnesium stearate.', 'In addition, the coating for the tablets contains artificial blackberry flavor,', 'hypromellose, macrogol and titanium dioxide.', 'Metformin is an antihyperglycemic agent which improves glucose tolerance in', 'patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma', 'glucose. Metformin decreases hepatic glucose production, decreases intestinal', 'absorption of glucose, and improves insulin sensitivity by increasing peripheral', 'glucose uptake and utilization. With Metformin therapy, insulin secretion remains', 'unchanged while fasting insulin levels and day-long plasma insulin response may', 'decrease.', 'Formulation and Stability: Metformin is available as an oral immediate release', 'solution (100mg/mL), an oral extended release suspension (100mg/mL), 500 mg,', '850 mg and 1000 mg immediate release tablets, and 500 mg and 750 mg extended', 'release tablets. The immediate release oral solution should be stored at 15\u00b0C to', '30\u00b0C (59\u00b0F to 86\u00b0F). The extended release oral suspension should be stored at 20\u00b0C', 'to 25\u00b0C (68\u00b0F to 77\u00b0F) with excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F).', 'Any unused portion of the reconstituted extended release oral suspension should be', 'discarded after 100 days. Tablet formulations should be stored protected from light', 'and moisture at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F with excursions permitted to 15\u00b0C to', '30\u00b0C (59\u00b0F to 86\u00b0F).', 'Supplier: Commercially available', 'Toxicity: Toxicities include chest discomfort, flushing, palpitations, chills,', 'dizziness, headache, taste disorder, diaphoresis, nail disease, skin rash, decreased', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB appro date 00-00-00', 'IRB NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}